Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Dapagliflozin as Add-on Therapy on Glycemic Status and Quality of Life in Type 2 Diabetic Patients

NCT06326034 is registered in ClinicalTrials.gov with Mohammed Mahmood Mohammed as lead sponsor.

NCT NCT06326034
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06326034 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Dapagliflozin as Add-on Therapy on Glycemic Status and Quality of Life in Type 2 Diabetic Patients
Lead sponsor
Mohammed Mahmood Mohammed
Phase
Phase 4
Overall status
Completed
Start date
May 1, 2022
Completion date
January 1, 2023
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic nephropathy type 2